The aim of studying and bibliography

The main aim of study: Familiarization with basic principles of drugs action at molecular level, classical methods of molecular farmacology and new trends in pharmacology, pharmacogenetics ang pharmacogenomics.

The general information about the module: Module implemented in the sixth semester of the 1st degree studies as a basic for Pharmaceutical Engineering. Implemented as 15 hours of lectures, ending with a pass.

Teaching materials: Strona internetowa dla studentów: http://www.prz.nrl.sk

Bibliography required to complete the module

Bibliography used during lectures

1	Kostowski W.:	Farmakologia. Podstawy farmakoterapii	PZWL, Warszawa.	2003
2	Michał Wiciński, Aleksander Marciniak	Skrypt do ćwiczeń z farmakologii	Wydawnictwo Wyższej Szkoły Inżynierii i Zdrowia w Warszawie 02-366 Warszawa, ul. Bitwy Warszawskiej 1920.	2018
3	Kalow, Meyer, Tyndale	Pharmacogenomics	Marcel Dekker.	2001

Bibliography used during classes/laboratories/others

1

J. Legáth

Ćwiczenia - Molekularne podstawy farmakologii

http://www.prz.nrl.sk.

2018

Basic requirements in category knowledge/skills/social competences

Formal requirements: Positively finished courses: Immunological techniques in biotechnology, Biochemistry, Enzymology

Basic requirements in category knowledge: Basic knowledge of biochemistry, immunology and enzymology

Basic requirements in category skills: Self-education and searching for information skills.

Basic requirements in category social competences: Individual and team work skills.

Module outcomes

MEK	The student who completed the module	Types of classes / teaching methods leading to achieving a given outcome of teaching	Methods of verifying every mentioned outcome of teaching	Relationships with KEK	Relationships with PRK
01	Knows basic terminology and properly uses pharmacological nomenclature.	lecture	written test	K_W02+	P6S_WG
02	Has a basic knowledge of the drug development process and using of natural drugs and biopharmaceuticals	lecture	written test	K_W09+	P6S_WG
03	Has a basic knowledge about causes of diseases.	lecture	written test	K_W09+	P6S_WG
04	Knows basic molecular targets of drugs.	lecture	written test	K_W09+	P6S_WG
05	Knows fundamental research methods in molecular oharmacology.	lecture, laboratory work	written test	K_K01+	P6S_KK
06	Knows new trends and ethical issues of contemporary pharmacology.	lecture, laboratory work	written test	K_K01+	P6S_KK

Attention: Depending on the epidemic situation, verification of the achieved learning outcomes specified in the study program, in particular credits and examinations at the end of specific classes, can be implemented remotely (real-time meetings).

The syllabus of the module

Sem.	TK	The content	realized in	MEK
5	TK01	Introduction in to molecular pharmacology, definition, terminology, methodology and introduction on the drug development.	W01	MEK01 MEK02
5	TK02	The basis of enzymology. Enzymes of nuclei, mitochondrial enzymes, extra cellular enzymes and metabolism of drugs, pharmacogenetics and pharmacogenomics.	W02	MEK01 MEK04
5	TK03	Drugs and cell membrane, mechanisms of transporting, mechanisms of signal transduction, ionic canals, chemoreceptors, classify of receptors, receptor theory.	W03	MEK04
5	TK04	Cells organization, tissue and organs, organs system, mechanisms of cell differentiation. Transmission of signal between cells, potential of action, mediators, synapses. Influence of formation and transmission of excitement with drugs – mechanism of action.	W04	MEK03 MEK04
5	TK05	Methodology and methods of pharmacogenetics and pharmacogenomics – modeling of enzymobiotic and others biological active proteins	W05	MEK05 MEK06
5	TK06	Molecular base of choice pathophysiological state (neurogenerative diseases, cardiovascular diseases etc.) – molecular influence this states with drugs.	W06	MEK03 MEK04
5	TK07	Cells parasites: viruses, bacteriophage, his function in the science and pharmacology. Prions diseases.	W07	MEK03
5	TK08	Mechanism of action of antivirotics, classify of antivirotics, desinficiens and resistance.	W08	MEK03 MEK04
5	TK09	Mutagenity, carcinogenity, tumor, mechanism of action of cytostatics, resistance.	W09	MEK03 MEK04
5	TK10	Cells culture – cultivate, reproduce and preparation for testing of new anti-tumors drugs	W10	MEK05 MEK06
5	TK11	Structure of proteins and utilization of change of structure of proteins to development of new drugs. Value of protein p53.	W11	MEK02 MEK03 MEK04
5	TK12	Molecular base of immunofarmacology and immunotoxicology, inflammation, allergy, Drugs, which influence immune system.	W12	MEK01 MEK03 MEK04
5	TK13	Natural drugs of plants or animal origin – preparation and separation, mechanism of molecular action in the organisms.	W13	MEK02
5	TK14	Application and use molecular methods in the pharmacology - biopharmaceuticals.	W14	MEK02 MEK06
5	TK15	GMO and their products and ethic problem of molecular biology and pharmacology.	W15	MEK01 MEK06

The student's effort

The type of classes	The work before classes	The participation in classes	The work after classes
Lecture (sem. 5)		contact hours: 15.00 hours/sem.
Advice (sem. 5)
Credit (sem. 5)

The way of giving the component module grades and the final grade

The type of classes	The way of giving the final grade
Lecture
The final grade	The final note (OK) is calculated from written test including issues from lectures. 100 points; 51-60p. - 3.0; 61-70p. - 3.5; 71-80p. - 4.0; 81-90p. - 4.5; 91-100p. - 5.0

Sample problems

Required during the exam/when receiving the credit
(-)

Realized during classes/laboratories/projects
(-)

Others
(-)

Can a student use any teaching aids during the exam/when receiving the credit : no

The contents of the module are associated with the research profile: yes

1	A. Bocian; J. Buczkowicz; K. Hus; J. Legath; T. Litschka-Koen; V. Petrilla; M. Petrillova; M. Pietrowska	Venom diversity in Naja mossambica: Insights from proteomic and immunochemical analyses reveal intraspecific differences	2024
2	A. Bocian; J. Gikunju; K. Hus; J. Kimotho ; J. Legath; E. Manson; K. Mutinda; V. Petrilla	Development of an Inhibition Enzyme-Linked Immunosorbent Assay (ELISA) Prototype for Detecting Cytotoxic Three-Finger Toxins (3FTxs) in African Spitting Cobra Venoms	2022
3	A. Bocian; K. Hus; J. Kimani; J. Kimotho ; M. Kyama; J. Legath; E. Manson; V. Petrilla	Development and Characterization of Anti-Naja ashei Three-Finger Toxins (3FTxs)-Specific Monoclonal Antibodies and Evaluation of Their In Vitro Inhibition Activity	2022
4	A. Barbasz; A. Bocian; A. Czyżowska; B. Dyba; K. Hus; J. Legath; V. Petrilla; M. Petrillova; E. Rudolphi-Szydło	Effects of 3FTx Protein Fraction from Naja ashei Venom on the Model and Native Membranes: Recognition and Implications for the Mechanisms of Toxicity	2021
5	A. Bocian; J. Buczkowicz; E. Ciszkowicz; K. Hus; K. Lecka-Szlachta; J. Legath; L. Legath; V. Petrilla; M. Petrillova; M. Pietrowska	Antimicrobial Activity of Protein Fraction from Naja ashei Venom Against Staphylococcus epidermidis	2020
6	A. Bocian; J. Buczkowicz; K. Hus; M. Jaromin; J. Legath; D. Łysiak; V. Petrilla; M. Petrillova; S. Sławek	Comparison of Methods for Measuring Protein Concentration in Venom Samples	2020
7	A. Bocian; K. Hus; E. Kuna; J. Legath; A. Lewińska; V. Petrilla; M. Petrillova; M. Wnuk	Evaluation of Antifungal Activity of Naja pallida and Naja mossambica Venoms against Three Candida Species	2020
8	A. Bocian; K. Hus; J. Legath; Ł. Marczak; V. Petrilla; M. Petrillova	Different research approaches in unraveling the venom proteome of Naja ashei	2020
9	A. Bocian; J. Buczkowicz; K. Hus; M. Jaromin; J. Legath	An effective method of isolating honey proteins	2019
10	J. Legath; D. Marcincakova; M. Miłek	Polyphenols Content, Antioxidant Activity, and Cytotoxicity Assessment of Taraxacum officinale Extracts Prepared through the Micelle-Mediated Extraction Method	2019
11	T. Csank; M. Falis; M. Fedorova; K. Hus; J. Legath; S. Marcincak; D. Marcincakova; D. Mudronova; P. Schusterova	Impact of Zinc Sulfate Exposition on Viability, Proliferation and Cell Cycle Distribution of Epithelial Kidney Cells	2019